Home LiteratureArticle Details
PMID: 33959510 Published · epublish English Journal Article

Disease Spectrum of Breast Cancer Susceptibility Genes.

Frontiers in oncology ·Vol. 11 ·2021-00-00 ·页码 663419

Wang J, Singh P, Yin K, Zhou J, Bao Y, Wu M, Pathak K, McKinley SK, Braun D, Hughes KS

Abstract

Pathogenic variants in cancer susceptibility genes can increase the risk of a spectrum of diseases, which clinicians must manage for their patients. We evaluated the disease spectrum of breast cancer susceptibility genes (BCSGs) with the aim of developing a comprehensive resource of gene-disease associations for clinicians. Twelve genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RECQL, STK11, and TP53), all of which have been conclusively established as BCSGs by the Clinical Genome Resource (ClinGen) and/or the NCCN guidelines, were investigated. The potential gene-disease associations for these 12 genes were verified and evaluated based on six genetic resources (ClinGen, NCCN, OMIM, Genetics Home Reference, GeneCards, and Gene-NCBI) and an additional literature review using a semiautomated natural language processing (NLP) abstract classification procedure. Forty-two diseases were found to be associated with one or more of the 12 BCSGs for a total of 86 gene-disease associations, of which 90% (78/86) were verified by ClinGen and/or NCCN. Four gene-disease associations could not be verified by either ClinGen or NCCN but were verified by at least three of the other four genetic resources. Four gene-disease associations were verified by the NLP procedure alone. This study is unique in that it systematically investigates the reported disease spectrum of BCSGs by surveying multiple genetic resources and the literature with the aim of developing a single consolidated, comprehensive resource for clinicians. This innovative approach provides a general guide for evaluating gene-disease associations for BCSGs, potentially improving the clinical management of at-risk individuals.

Keywords
breast cancer cancer genetic cancer susceptibility genes disease spectrum germline mutation
作者与单位
共 10 位作者,点击展开单位 / ORCID
Wang Jin
Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. | Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Singh Preeti
Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Yin Kanhua
Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. | Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, United States.
Zhou Jingan
Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. | Department of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Bao Yujia
Computer Science & Artificial Intelligence, Massachusetts Institute of Technology, Boston, MA, United States.
Wu Menghua
Computer Science & Artificial Intelligence, Massachusetts Institute of Technology, Boston, MA, United States.
Pathak Kush
Department of Surgical Oncology, P. D Hinduja Hospital, Mumbai, India.
McKinley Sophia K
Department of Surgery, Massachusetts General Hospital, Boston, MA, United States.
Braun Danielle
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, United States. | Department of Biostatistics, Harvard University T.H. Chan School of Public Health, Boston, MA, United States.
Hughes Kevin S
Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Article Info
Journal
Frontiers in oncology
Abbr.
Front Oncol
ISSN
2234-943X
Published
2021-00-00
电子出版
2021-00-20
页码
663419
Language
English
Country/Region
Switzerland
NLM ID
101568867
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com